Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SNR3C2
The experimentally established mechanism targets of Felodipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 2/20 | 0.61 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.58 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.58 |
| ▸ | CACNA1S known ✓ | Q13698 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Felodipine SCHEMBL29617765 | 1.00 | CYP2C9 (1.00) | CYP2C9CYP3A4HIF1AKDM4EMEN1 | |
| Felodipine SCHEMBL13460298 | 1.00 | CYP2C9 (1.00) | CYP2C9CYP3A4HIF1AKDM4EMEN1 | |
| Felodipine SCHEMBL920025 | 1.00 | CYP2C9 (1.00) | CYP2C9CYP3A4HIF1AKDM4EMEN1 | |
| (S)-Felodipine SCHEMBL26399 | 1.00 | CYP2C9 (1.00) | CYP2C9CYP3A4HIF1AKDM4EMEN1 | |
| (R)-Felodipine SCHEMBL54486 | 1.00 | CYP2C9 (1.00) | CYP2C9CYP3A4HIF1AKDM4EMEN1 | |
| (S)-Felodipine SCHEMBL29908048 | 1.00 | CYP2C9 (1.00) | CYP2C9CYP3A4HIF1AKDM4EMEN1 | |
| Felodipine SCHEMBL29049073 | 0.99 | CYP2C9 (0.98) | CYP2C9CYP3A4HIF1AKDM4EMEN1 | |
| Felodipine SCHEMBL27770064 | 0.99 | CYP2C9 (0.98) | CYP2C9CYP3A4HIF1AKDM4EMEN1 | |
| Felodipine SCHEMBL27608150 | 0.99 | CYP2C9 (0.98) | CYP2C9CYP3A4HIF1AKDM4EMEN1 | |
| Felodipine SCHEMBL28260282 | 0.98 | CYP2C9 (0.95) | CYP2C9CYP3A4HIF1AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 33935 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| WO-2026107071-A1 | COMBINATION THERAPY | Retension Pharmaceuticals, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026107412-A1 | SARCOSPAN MODULATION AND METHODS OF MEAT AND TISSUE CULTURE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-20260115145-A1 | Method for Enhancing Drug Solubility and Preparing a Drug Composite Material with Enhanced Solubility | PHARMAEASE TECH LTD (CN) | 2026-04-30 | — | — | US | claimed |
| EP-3934654-B1 | ISTAROXIME OR ITS METABOLITE PST-3093 FOR USE AS INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS INC (US) | 2026-04-29 | — | — | EP | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4724060-A1 | FORMULATIONS AND METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS | HB Biotech, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| WO-1986003676-A1 | SMALL PARTICLE FORMATION AND ENCAPSULATION | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1986-07-03 | — | — | WO | claimed |
| US-4584294-A | Fused tricyclic lactams as angiotensin converting enzyme inhibitors and as antihypertensive agents | MERCK & CO., INC. (US) | 1986-04-22 | — | — | US | claimed |
| EP-0166353-A2 | Benzofused lactams useful as antihypertensive agents and as cholecystokinin antagonists | MERCK & CO. INC. (US) | 1986-01-02 | — | — | EP | claimed |
| EP-0163237-A2 | Di- and tri-peptidal renin inhibitors | MERCK & CO. INC. (US) | 1985-12-04 | — | — | EP | claimed |
| WO-1985000110-A1 | SMALL PARTICLE FORMATION | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1985-01-17 | — | — | WO | claimed |
| EP-0130160-A2 | Small particle formation | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1985-01-02 | — | — | EP | claimed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |
| EP-0095450-A2 | Processes for preparing therapeutically active dihydropyridines and intermediates for the processes | Aktiebolaget Hässle (SE) | 1983-11-30 | — | — | EP | claimed |
| EP-0007293-B1 | 2,6-DIMETHYL-4-(2,3-DICHLOROPHENYL)-1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLIC ACID-3-METHYL ESTER-5-ETHYL ESTER HAVING HYPOTENSIVE PROPERTIES, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING IT | Aktiebolaget Hässle (SE) | 1982-06-23 | — | — | EP | claimed |
| US-4264611-A | HYPOTENSIVE AGENTS | AKTIEBOLAGET HASSLE (SE) | 1981-04-28 | — | — | US | claimed |